Practice Management

Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.

As some assets appreciate in value and others lose value, your portfolio’s allocation changes. Rebalancing is the remedy for asset drift and an important part of maintaining a healthy investment portfolio.

The practical application of medical necessity has taken many forms, and in this increasingly complex world of health care, understanding these applications has become a critical component of your business.

Following some basic guidelines will ensure the beneficiary designations you make are accurate and up to date.

In this article, Robert A. Dowling, MD, describes what urologists need to know about the Quality category of MIPS and nuances of the scoring methodology.

"Determining what to invest in should be based primarily on the needs, temperament, and available resources of each individual or family," write Jeff Witz, CFP, and David Zemon.

In this "Coding Q&A," the Painters also answer a question regarding coding for sling and cystocele repair with mesh repair.

Other pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.

The provision of health care via technology and without direct eye-to-eye and skin-to-skin contact is an area of growing interest in the U.S. It is also an area of great concern. One of the key conundrums surrounding telemedicine is the when, how, and what to pay for the service.

Value-based payment models tend to fall into three general categories: shared savings programs, capitation models, and episode-of-care models. In this article, Robert A. Dowling, MD, reviews the current landscape of these payment models, including public and private-sector models that may serve as examples for urology.

With the U.S. stock market reaching record highs, it’s important to know how to prepare for an eventual fall. Plus, tax credits may be available for tuition payers.

Neil Baum, MD, and Randy Bauman discuss their tips to making the transition from practice seller to buyer as seamless as possible to keep patient retention rates high.

When trying to determine how much is enough when saving for retirement, there are many elements that must be considered. Plus, weigh these pros and cons when deciding how long to receive payments from an immediate annuity.

Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.

Other products discussed include an updated prostate tissue ablation device, a contrast agent for voiding ultrasonography, a bladder cancer test and more.

This article will discuss the concept of practice valuation and how to go from abstraction to dollars or how to make dollars and “cents” of the process of putting a dollar value on a urologic practice.

Each year, the Office of the Inspector General at the Department of Health and Human Services publishes a summary of its activities and a work plan for the coming year. What follows is a summary of new topics in the FY2017 work plan that may be of interest to urologists.

Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.